Epix MS-325 User Fee Goal Is Oct. 15; Broad Vascular Imaging Claim Sought
This article was originally published in Pharmaceutical Approvals Monthly
FDA’s decision to assign Epix’s vascular imaging agent MS-325 a standard review sets the user fee goal for the NDA at Oct. 15.
You may also be interested in...
Schering AG/Epix MS-325 imaging agent requires additional clinical studies, FDA says in “approvable” letter. Outstanding questions relate to the non-contrast comparator scanning methods used in Phase III trials and statistical treatment of uninterpretable baseline scans
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011